I

InDex Pharmaceuticals Holding AB
STO:FLERIE

Watchlist Manager
InDex Pharmaceuticals Holding AB
STO:FLERIE
Watchlist
Price: 45 SEK 0.78% Market Closed
Market Cap: 3.5B SEK
Have any thoughts about
InDex Pharmaceuticals Holding AB?
Write Note

InDex Pharmaceuticals Holding AB
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

InDex Pharmaceuticals Holding AB
Cost of Revenue Peer Comparison

Comparables:
CALTX
CAMX
S
SECARE
IRLAB A
MOB

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
I
InDex Pharmaceuticals Holding AB
STO:FLERIE
Cost of Revenue
-kr127m
CAGR 3-Years
-305%
CAGR 5-Years
-251%
CAGR 10-Years
N/A
Calliditas Therapeutics AB
STO:CALTX
Cost of Revenue
-kr104.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Camurus AB
STO:CAMX
Cost of Revenue
-kr127.2m
CAGR 3-Years
-29%
CAGR 5-Years
-70%
CAGR 10-Years
N/A
S
Swedencare AB (publ)
STO:SECARE
Cost of Revenue
-kr1.1B
CAGR 3-Years
-68%
CAGR 5-Years
-107%
CAGR 10-Years
N/A
IRLAB Therapeutics AB
STO:IRLAB A
Cost of Revenue
-kr128.4m
CAGR 3-Years
-25%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Moberg Pharma AB (publ)
STO:MOB
Cost of Revenue
kr0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is InDex Pharmaceuticals Holding AB's Cost of Revenue?
Cost of Revenue
-127m SEK

Based on the financial report for Jun 30, 2024, InDex Pharmaceuticals Holding AB's Cost of Revenue amounts to -127m SEK.

What is InDex Pharmaceuticals Holding AB's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-251%

Over the last year, the Cost of Revenue growth was -112%. The average annual Cost of Revenue growth rates for InDex Pharmaceuticals Holding AB have been -305% over the past three years , -251% over the past five years .

Back to Top